These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27322375)

  • 1. Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
    Kolios AG; Yawalkar N; Anliker M; Boehncke WH; Borradori L; Conrad C; Gilliet M; Häusermann P; Itin P; Laffitte E; Mainetti C; French LE; Navarini AA
    Dermatology; 2016; 232(4):385-406. PubMed ID: 27322375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future oral systemic therapies for psoriasis.
    Kelly JB; Foley P; Strober BE
    Dermatol Clin; 2015 Jan; 33(1):91-109. PubMed ID: 25412786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
    Nast A; Gisondi P; Ormerod AD; Saiag P; Smith C; Spuls PI; Arenberger P; Bachelez H; Barker J; Dauden E; de Jong EM; Feist E; Jacobs A; Jobling R; Kemény L; Maccarone M; Mrowietz U; Papp KA; Paul C; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Yawalkar N
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2277-94. PubMed ID: 26481193
    [No Abstract]   [Full Text] [Related]  

  • 4. [Systemic therapy of psoriasis].
    Altmeyer P; Nüchel C
    Dtsch Med Wochenschr; 1996 Dec; 121(51-52):1605-7. PubMed ID: 9011488
    [No Abstract]   [Full Text] [Related]  

  • 5. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.
    Nast A; Boehncke WH; Mrowietz U; Ockenfels HM; Philipp S; Reich K; Rosenbach T; Sammain A; Schlaeger M; Sebastian M; Sterry W; Streit V; Augustin M; Erdmann R; Klaus J; Koza J; Muller S; Orzechowski HD; Rosumeck S; Schmid-Ott G; Weberschock T; Rzany B; ;
    J Dtsch Dermatol Ges; 2012 Mar; 10 Suppl 2():S1-95. PubMed ID: 22386073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.
    Nast A; Kopp IB; Augustin M; Banditt KB; Boehncke WH; Follmann M; Friedrich M; Huber M; Kahl C; Klaus J; Koza J; Kreiselmaier I; Mohr J; Mrowietz U; Ockenfels HM; Orzechowski HD; Prinz J; Reich K; Rosenbach T; Rosumeck S; Schlaeger M; Schmid-Ott G; Sebastian M; Streit V; Weberschock T; Rzany B; ;
    J Dtsch Dermatol Ges; 2007 Jul; 5 Suppl 3():1-119. PubMed ID: 17615051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
    Menter A; Gelfand JM; Connor C; Armstrong AW; Cordoro KM; Davis DMR; Elewski BE; Gordon KB; Gottlieb AB; Kaplan DH; Kavanaugh A; Kiselica M; Kivelevitch D; Korman NJ; Kroshinsky D; Lebwohl M; Leonardi CL; Lichten J; Lim HW; Mehta NN; Paller AS; Parra SL; Pathy AL; Prater EF; Rahimi RS; Rupani RN; Siegel M; Stoff B; Strober BE; Tapper EB; Wong EB; Wu JJ; Hariharan V; Elmets CA
    J Am Acad Dermatol; 2020 Jun; 82(6):1445-1486. PubMed ID: 32119894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. German S3-guidelines on the treatment of psoriasis vulgaris (short version).
    Nast A; Boehncke WH; Mrowietz U; Ockenfels HM; Philipp S; Reich K; Rosenbach T; Sammain A; Schlaeger M; Sebastian M; Sterry W; Streit V; Augustin M; Erdmann R; Klaus J; Koza J; Müller S; Orzechowski HD; Rosumeck S; Schmid-Ott G; Weberschock T; Rzany B; ;
    Arch Dermatol Res; 2012 Mar; 304(2):87-113. PubMed ID: 22350179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Carretero G; Ribera M; Belinchón I; Carrascosa JM; Puig L; Ferrandiz C; Dehesa L; Vidal D; Peral F; Jorquera E; González-Quesada A; Muñoz C; Notario J; Vanaclocha F; Moreno JC;
    Actas Dermosifiliogr; 2013 Sep; 104(7):598-616. PubMed ID: 23891453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
    Katz HI
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S62-8. PubMed ID: 9344188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
    Armstrong AW; Aldredge L; Yamauchi PS
    J Cutan Med Surg; 2016 May; 20(3):196-206. PubMed ID: 26712930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Puig L; Carrascosa JM; Carretero G; de la Cueva P; Lafuente-Urrez RF; Belinchón I; Sánchez-Regaña M; García-Bustínduy M; Ribera M; Alsina M; Ferrándiz C; Fonseca E; García-Patos V; Herrera E; López-Estebaranz JL; Marrón SE; Moreno JC; Notario J; Rivera R; Rodriguez-Cerdeira C; Romero A; Ruiz-Villaverde R; Taberner R; Vidal D;
    Actas Dermosifiliogr; 2013 Oct; 104(8):694-709. PubMed ID: 24018211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients with psoriasis.
    Croney S
    Br J Nurs; 2017 Mar; 26(5):260-262. PubMed ID: 28328264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
    Ryan C; Kirby B
    Dermatol Clin; 2015 Jan; 33(1):41-55. PubMed ID: 25412782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional systemic agents for psoriasis. A systematic review.
    Strober BE; Siu K; Menon K
    J Rheumatol; 2006 Jul; 33(7):1442-6. PubMed ID: 16724368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practice.
    Burden-Teh E; Lam ML; Taibjee SM; Taylor A; Webster S; Dolman S; Jury C; Caruana D; Darne S; Carmichael A; Natarajan S; McPherson T; Moore A; Katugampola R; Kalavala M; Al-Ismail D; Richards L; Jones V; Batul Syed S; Glover M; Hughes J; Anderson E; Hughes B; Helbling I; Murphy R
    Br J Dermatol; 2015 Aug; 173(2):614-8. PubMed ID: 25601323
    [No Abstract]   [Full Text] [Related]  

  • 17. Dermatologists' adherence to the guideline of the Dutch Society of Dermatology and Venereology with respect to the treatment with methotrexate for severe chronic plaque psoriasis: results from a Dutch survey.
    Berends MA; de Jong EM; van de Kerkhof PC; Gerritsen MJ
    Dermatology; 2007; 215(1):45-52. PubMed ID: 17587839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial.
    Fallah Arani S; Neumann H; Hop WC; Thio HB
    Br J Dermatol; 2011 Apr; 164(4):855-61. PubMed ID: 21175564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
    Wilsmann-Theis D; Frambach Y; Philipp S; Weyergraf AJ; Jacobi A; Mössner R; Gerdes S
    Dermatology; 2015; 230(2):119-27. PubMed ID: 25661583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
    Akçali C; Guven EH; Kirtak N; Inaloz HS; Ozgoztasi O; Guvenc U
    J Int Med Res; 2014 Oct; 42(5):1118-22. PubMed ID: 25143337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.